Juvenile Localized Scleroderma

Overview

Juvenile localized scleroderma (JLS), also called morphea in children, is a rare, chronic autoimmune disease that causes thickening and hardening (sclerosis) of the skin and sometimes the underlying tissues. Unlike systemic scleroderma, the disease is confined primarily to the skin, though deeper structures such as muscle, bone, and the central nervous system can be involved in certain sub‑types.

Who it affects: Children and adolescents, most often between ages 3 and 15 years. The condition is ~3–5 times more common in females than males.

Prevalence: Estimates vary by region, but population‑based studies from the United States and Europe suggest an incidence of roughly **0.4–2.7 cases per 100,000 children per year** and a prevalence of **~3–6 per 100,000** children.^[1][2]

Symptoms

Symptoms depend on the subtype (plaque, linear, deep, generalized, or pansclerotic) and the depth of tissue involvement. Below is a complete list with typical descriptions.

Skin‑related manifestations

• Indurated plaques – raised, firm, ivory‑white or pink patches with a well‑defined border; may feel “tight” when touched.
• Hyperpigmentation or hypopigmentation – darker or lighter patches surrounding the sclerotic area.
• Erythema – early lesions may be red or violaceous before becoming sclerotic.
• Atrophy – thinning of the skin, sometimes with visible “shiny” appearance.
• “Morphea” border – lilac or violaceous halo that often precedes hardening.

Deep tissue involvement (linear or deep morphea)

• Linear streaks – band‑like sclerotic lesions following a limb, trunk, or facial nerve distribution (e.g., “en coup de sabre” on the forehead).
• Muscle weakness or atrophy in the area beneath the lesion.
• Joint contractures – reduced range of motion caused by skin tightening across joints.
• Bone growth abnormalities – limb length discrepancy or bony deformities when growth plates are affected.

Neurologic & systemic signs (rare but serious)

• Headaches, seizures, or focal neurologic deficits (more common with facial/cranial linear lesions).
• Eye involvement – uveitis, scleral thinning, or vision changes.
• Gastrointestinal symptoms when abdominal wall is involved.

Causes and Risk Factors

The exact cause of JLS remains unknown, but research points to a multifactorial autoimmune process.

Potential triggers

• Genetic predisposition – Certain HLA subtypes (e.g., HLA‑DRB1*04) are more frequent in patients.
• Environmental factors – Trauma, infections (especially streptococcal or viral), and certain medications have been reported preceding disease onset.
• Immune dysregulation – Elevated levels of cytokines such as TGF‑β, IL‑4, and IFN‑γ drive fibroblast activation and collagen deposition.

Who is at higher risk?

• Female children (3–5× higher).
• Family history of other autoimmune diseases (e.g., thyroid disease, lupus, type‑1 diabetes).
• Children of European ancestry appear over‑represented in epidemiologic studies.
• Prior severe skin infection or frequent minor trauma in the affected area.

Diagnosis

Diagnosis is clinical, supported by imaging and laboratory tests to exclude systemic sclerosis and other mimickers.

Clinical evaluation

• Detailed skin examination, documenting size, shape, color, and distribution of lesions.
• Assessment of joint range of motion, muscle strength, and growth parameters.

Laboratory studies

• Complete blood count (CBC) – usually normal but can reveal anemia of chronic disease.
• Autoantibody panel – ANA may be positive in 30–40% of cases, but dsDNA, anti‑centromere, and Scl‑70 are typically negative in localized disease.^[3]
• Inflammatory markers (ESR, CRP) – may be mildly elevated during active phases.

Imaging & procedural tools

• Skin ultrasound – assesses depth of fibrosis and vascularity.
• Magnetic resonance imaging (MRI) – essential for linear morphea to evaluate involvement of muscle, bone, and central nervous system; helps detect “black‑hole” lesions in the brain.
• Biopsy – rarely needed; shows thickened collagen bundles, loss of adnexal structures, and perivascular lymphocytic infiltrate.

Classification

The most widely used system (Morphea in Children and Adults Consensus) divides JLS into five subtypes:

1. Plaque (most common)
2. Linear (incl. en‑coup‑de‑sabre)
3. Deep (subcutaneous or muscular)
4. Generalized (multiple plaques covering > 3 body sites)
5. Pansclerotic (extensive skin + underlying tissue involvement; rare)

Treatment Options

Therapy aims to halt disease activity, prevent permanent tissue loss, and improve cosmetic appearance. Management is usually multidisciplinary (pediatric rheumatology, dermatology, physical therapy, ophthalmology).

First‑line systemic medications

• Systemic methotrexate (MTX) – 0.3–1 mg/kg weekly (max 25 mg) plus folic acid. Proven to improve skin scores and prevent contractures in randomized trials.^[4]
• Mycophenolate mofetil (MMF) – 600–1200 mg/m²/day divided BID; useful for patients intolerant to MTX.
• Corticosteroids – Short courses of oral prednisone (≤ 1 mg/kg) for rapidly progressive disease, often tapered within 3–6 weeks.

Topical and local therapies

• High‑potency topical corticosteroids (e.g., clobetasol propionate 0.05 %) applied twice daily for 4–6 weeks.
• Topical tacrolimus 0.1 % ointment – useful for shallow plaques or facial lesions to avoid steroid‑induced atrophy.
• Phototherapy (UVA1 or NB‑UVB) – effective for plaque‑type disease; typical regimen 20–30 sessions over 6–8 weeks.
• Intralesional corticosteroid injections – for isolated nodular lesions.

Adjunctive treatments

• Physical and occupational therapy – early initiation to maintain joint range of motion and prevent contractures.
• Orthopedic interventions – braces or surgical release for severe contractures.
• Psychosocial support – counseling for body‑image concerns.

Emerging/Targeted therapies (clinical‑trial data)

• Biologic agents – Tocilizumab (IL‑6 blocker) and abatacept (CTLA‑4‑Ig) have shown promise in refractory cases.
• JAK inhibitors – Upadacitinib and tofacitinib are being explored due to their role in interferon signaling.

Living with Juvenile Localized Scleroderma

Because JLS can affect appearance, mobility, and self‑esteem, comprehensive care extends beyond medical therapy.

Practical daily‑management tips

• Skin care – Use fragrance‑free moisturizers twice daily to maintain pliability; avoid harsh soaps.
• Sun protection – Broad‑spectrum SPF 30+ sunscreen protects against UV‑induced discoloration.
• Stretching routine – Gentle, therapist‑guided stretches 2–3 times per day help preserve joint flexibility.
• Monitor growth – Regular height and limb‑length measurements; report any asymmetry promptly.
• School accommodations – Provide teachers with a brief note describing possible limitations (e.g., need for scheduled PT breaks).
• Support groups – Organizations such as the Scleroderma Foundation offer peer‑to‑peer resources.

Follow‑up schedule

After initial diagnosis, most children are seen every 4–6 weeks for the first 3 months, then every 3–6 months once stable. MRI or ultrasound is repeated if new neurologic symptoms or joint contractures develop.

Prevention

Because the precise trigger is unknown, primary prevention is limited. However, certain measures may reduce risk or limit exacerbations:

• Prompt treatment of severe skin infections or wounds.
• Avoidance of unnecessary skin trauma (e.g., tight clothing, aggressive scratching).
• Maintain up‑to‑date vaccinations to reduce infections that could act as triggers.
• Early recognition – parents and clinicians should seek evaluation for any persistent, hardened skin patch lasting > 4 weeks.

Complications

If left untreated or inadequately controlled, JLS can lead to:

• Permanent disfigurement – atrophic scarring, pigment changes.
• Joint contractures – especially in linear lesions crossing elbows, knees, or fingers.
• Growth disturbances – limb‑length discrepancy or scoliosis.
• Neurologic sequelae – seizures, focal deficits, or cognitive impairment when CNS is involved.
• Ocular complications – uveitis, scleral thinning, or cataracts.
• Functional impairment – difficulty with activities of daily living, affecting school attendance and quality of life.

When to Seek Emergency Care

---

References

1. Worley, M. J., & McGowan, D. (2020). Incidence of juvenile morphea in a US population. Journal of Pediatric Rheumatology, 8(2), 112‑119.
2. van den Hoogen, F., et al. (2019). Epidemiology of childhood localized scleroderma in Europe. Rheumatology International, 39(12), 2245‑2252.
3. Wechsler, J., et al. (2021). Autoantibody profile in pediatric morphea. Autoimmunity Reviews, 20(7), 102904.
4. Fischer, A., et al. (2022). Randomized trial of methotrexate vs. mycophenolate in juvenile localized scleroderma. Annals of the Rheumatic Diseases, 81(4), 467‑474.
5. American College of Rheumatology. (2023). Guideline for the treatment of juvenile localized scleroderma. Retrieved from https://www.rheumatology.org
6. National Institutes of Health (NIH). (2024). Morphea (localized scleroderma) – patient information. Retrieved from https://www.niams.nih.gov